(JAZZ) Jazz Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00B4Q5ZN47

Oxybate,Sleep,Seizure,Cancer,HEMATOLOGY

JAZZ EPS (Earnings per Share)

EPS (Earnings per Share) of JAZZ over the last years for every Quarter: "2020-09": 4.31, "2020-12": 4, "2021-03": 3.92, "2021-06": 3.9, "2021-09": 4.2, "2021-12": 4.21, "2022-03": 3.73, "2022-06": 4.3, "2022-09": 5.17, "2022-12": -0.07, "2023-03": 3.95, "2023-06": 4.51, "2023-09": 4.84, "2023-12": 5.02, "2024-03": 2.68, "2024-06": 5.3, "2024-09": 6.61, "2024-12": 6.6, "2025-03": -1.52, "2025-06": -8.25, "2025-09": 0,

JAZZ Revenue

Revenue of JAZZ over the last years for every Quarter: 2020-09: 600.888, 2020-12: 665.517, 2021-03: 607.581, 2021-06: 751.811, 2021-09: 838.115, 2021-12: 896.731, 2022-03: 813.721, 2022-06: 932.878, 2022-09: 940.652, 2022-12: 972.123, 2023-03: 892.812, 2023-06: 957.317, 2023-09: 972.14, 2023-12: 1011.935, 2024-03: 901.983, 2024-06: 1023.825, 2024-09: 1054.969, 2024-12: 1088.173, 2025-03: 897.841, 2025-06: 1045.712, 2025-09: null,

Description: JAZZ Jazz Pharmaceuticals

Jazz Pharmaceuticals PLC is a pharmaceutical company that develops and commercializes treatments for various serious conditions, including narcolepsy, seizures, leukemia, and lung cancer. The companys product portfolio includes Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos, which are used to treat a range of diseases. Jazz Pharmaceuticals has a strong pipeline of products in development, including Zanidatamab, Suvecaltamide, JZP815, JZP898, JZP441, JZP324, and JZP150, which are being tested for various indications.

From a financial perspective, Jazz Pharmaceuticals has a market capitalization of approximately $6.95 billion USD, indicating a significant presence in the pharmaceutical industry. The companys price-to-earnings ratio is around 15.61, suggesting a relatively stable valuation. Additionally, the return on equity (RoE) is 11.90%, indicating a decent return for shareholders. Key performance indicators (KPIs) to watch include revenue growth, R&D expenses as a percentage of revenue, and the progression of pipeline products through clinical trials.

The companys partnerships with other pharmaceutical companies, such as Redx Pharma plc, Autifony Therapeutics Limited, and Zymeworks Inc., demonstrate its commitment to collaboration and innovation. With a diverse portfolio of products and a strong pipeline, Jazz Pharmaceuticals is well-positioned for future growth. Key metrics to monitor include the commercial success of its products, particularly Xywav and Epidiolex, as well as the advancement of its pipeline products, such as Zanidatamab and Suvecaltamide.

To further evaluate Jazz Pharmaceuticals prospects, it is essential to analyze its revenue breakdown by product, geographic region, and customer segment. Additionally, assessing the companys cash flow generation, debt levels, and dividend policy can provide insights into its financial health and ability to invest in R&D. By closely monitoring these KPIs, investors can gain a deeper understanding of the companys strengths and weaknesses, ultimately informing their investment decisions.

JAZZ Stock Overview

Market Cap in USD 8,304m
Sub-Industry Pharmaceuticals
IPO / Inception 2007-06-01

JAZZ Stock Ratings

Growth Rating -9.04%
Fundamental 53.4%
Dividend Rating -
Return 12m vs S&P 500 5.97%
Analyst Rating 4.44 of 5

JAZZ Dividends

Currently no dividends paid

JAZZ Growth Ratios

Growth Correlation 3m 90.1%
Growth Correlation 12m 0.9%
Growth Correlation 5y -77.3%
CAGR 5y -0.12%
CAGR/Max DD 3y (Calmar Ratio) 0.00
CAGR/Mean DD 3y (Pain Ratio) -0.01
Sharpe Ratio 12m 1.21
Alpha 18.79
Beta 0.243
Volatility 25.39%
Current Volume 365.1k
Average Volume 20d 649.5k
Stop Loss 130.9 (-3.1%)
Signal 0.18

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (-404.8m TTM) > 0 and > 6% of Revenue (6% = 245.2m TTM)
FCFTA 0.12 (>2.0%) and ΔFCFTA 2.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 31.30% (prev 54.37%; Δ -23.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.12 (>3.0%) and CFO 1.32b > Net Income -404.8m (YES >=105%, WARN >=100%)
Net Debt (4.24b) to EBITDA (447.1m) ratio: 9.49 <= 3.0 (WARN <= 3.5)
Current Ratio 1.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (61.2m) change vs 12m ago -12.11% (target <= -2.0% for YES)
Gross Margin 88.71% (prev 85.52%; Δ 3.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 36.64% (prev 34.41%; Δ 2.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -1.07 (EBITDA TTM 447.1m / Interest Expense TTM 211.0m) >= 6 (WARN >= 3)

Altman Z'' 0.65

(A) 0.12 = (Total Current Assets 3.35b - Total Current Liabilities 2.07b) / Total Assets 10.94b
(B) 0.02 = Retained Earnings (Balance) 191.3m / Total Assets 10.94b
(C) -0.02 = EBIT TTM -225.4m / Avg Total Assets 11.15b
(D) -0.04 = Book Value of Equity -294.4m / Total Liabilities 7.24b
Total Rating: 0.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 53.44

1. Piotroski 6.0pt = 1.0
2. FCF Yield 10.48% = 5.0
3. FCF Margin 30.96% = 7.50
4. Debt/Equity 1.47 = 1.51
5. Debt/Ebitda 9.49 = -2.50
6. ROIC - WACC (= -6.77)% = -8.46
7. RoE -10.03% = -1.67
8. Rev. Trend 44.55% = 3.34
9. EPS Trend -45.62% = -2.28

What is the price of JAZZ shares?

As of October 14, 2025, the stock is trading at USD 135.14 with a total of 365,059 shares traded.
Over the past week, the price has changed by -1.77%, over one month by +7.92%, over three months by +21.27% and over the past year by +21.71%.

Is Jazz Pharmaceuticals a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Jazz Pharmaceuticals is currently (October 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 53.44 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JAZZ is around 136.74 USD . This means that JAZZ is currently overvalued and has a potential downside of 1.18%.

Is JAZZ a buy, sell or hold?

Jazz Pharmaceuticals has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy JAZZ.
  • Strong Buy: 10
  • Buy: 6
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the JAZZ price?

Issuer Target Up/Down from current
Wallstreet Target Price 186.7 38.2%
Analysts Target Price 186.7 38.2%
ValueRay Target Price 147 8.8%

Last update: 2025-10-03 02:28

JAZZ Fundamental Data Overview

Market Cap USD = 8.30b (8.30b USD * 1.0 USD.USD)
P/E Forward = 6.3816
P/S = 2.032
P/B = 2.0785
P/EG = 5.5982
Beta = 0.243
Revenue TTM = 4.09b USD
EBIT TTM = -225.4m USD
EBITDA TTM = 447.1m USD
Long Term Debt = 4.34b USD (from longTermDebt, last quarter)
Short Term Debt = 1.04b USD (from shortTermDebt, last quarter)
Debt = 5.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.24b USD (from netDebt column, last quarter)
Enterprise Value = 12.07b USD (8.30b + Debt 5.43b - CCE 1.67b)
Interest Coverage Ratio = -1.07 (Ebit TTM -225.4m / Interest Expense TTM 211.0m)
FCF Yield = 10.48% (FCF TTM 1.27b / Enterprise Value 12.07b)
FCF Margin = 30.96% (FCF TTM 1.27b / Revenue TTM 4.09b)
Net Margin = -9.91% (Net Income TTM -404.8m / Revenue TTM 4.09b)
Gross Margin = 88.71% ((Revenue TTM 4.09b - Cost of Revenue TTM 461.2m) / Revenue TTM)
Gross Margin QoQ = 88.88% (prev 88.35%)
Tobins Q-Ratio = 1.10 (Enterprise Value 12.07b / Total Assets 10.94b)
Interest Expense / Debt = 0.87% (Interest Expense 47.4m / Debt 5.43b)
Taxrate = 2.32% (-17.1m / -735.6m)
NOPAT = -220.2m (EBIT -225.4m * (1 - 2.32%)) [loss with tax shield]
Current Ratio = 1.62 (Total Current Assets 3.35b / Total Current Liabilities 2.07b)
Debt / Equity = 1.47 (Debt 5.43b / totalStockholderEquity, last quarter 3.71b)
Debt / EBITDA = 9.49 (Net Debt 4.24b / EBITDA 447.1m)
Debt / FCF = 3.35 (Net Debt 4.24b / FCF TTM 1.27b)
Total Stockholder Equity = 4.04b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.70% (Net Income -404.8m / Total Assets 10.94b)
RoE = -10.03% (Net Income TTM -404.8m / Total Stockholder Equity 4.04b)
RoCE = -2.69% (EBIT -225.4m / Capital Employed (Equity 4.04b + L.T.Debt 4.34b))
RoIC = -2.25% (negative operating profit) (NOPAT -220.2m / Invested Capital 9.77b)
WACC = 4.51% (E(8.30b)/V(13.74b) * Re(6.91%) + D(5.43b)/V(13.74b) * Rd(0.87%) * (1-Tc(0.02)))
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -6.28%
[DCF Debug] Terminal Value 81.39% ; FCFE base≈1.18b ; Y1≈1.45b ; Y5≈2.46b
Fair Price DCF = 689.0 (DCF Value 41.80b / Shares Outstanding 60.7m; 5y FCF grow 24.66% → 3.0% )
EPS Correlation: -45.62 | EPS CAGR: 0.29% | SUE: -2.49 | # QB: 0
Revenue Correlation: 44.55 | Revenue CAGR: 3.93% | SUE: -0.04 | # QB: 0

Additional Sources for JAZZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle